References

Citations

1. Abel E, Lebwohl M (2005). Psoriasis. In DC Dale, DD Federman, eds., ACP Medicine, section 2, chap. 3. New York: WebMD.

2. Rapp SR, et al. (1999). Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology, 41(3): 401–407.

3. Guðjónsson JE, et al. (2002). HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. Journal of Investigative Dermatology, 118(2): 362–365.

4. Lee CS, Koo J (2007). Papulosquamous disorders. In RE Rakel, ET Bope, eds., Conn's Current Therapy, pp. 931–936. Philadelphia: Elsevier Saunders.

5. Behnam SM, et al. (2005). Smoking and psoriasis. Skinmed, 4(3): 174–176.

6. Setty AR, et al. (2007). Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Archives of Internal Medicine, 167(15): 1670–1675.

7. Leman J, Burden D (2001). Psoriasis in children: A guide to its diagnosis and management. Paediatric Drugs, 3(9): 673–680.

8. Christophers E, Mrowietz U (2003). Psoriasis. In IM Freedberg et al., eds., Fitzpatrick's Dermatology in General Medicine, 6th ed., vol. 1, pp. 407–427. New York: McGraw-Hill.

9. Menter A, Griffiths CEM (2007). Current and future management of psoriasis. Lancet, 370(9583): 272–284.

10. Fortune DG, et al. (2002). A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy. British Journal of Dermatology, 146(3): 458–465.

11. Pardasani A, et al. (2000). Treatment of psoriasis: An algorithm-based approach for primary care physicians. American Family Physician, 61(3): 725–733.

12. Abramowicz M (2005). Drugs for acne, rosacea and psoriasis. Treatment Guidelines From the Medical Letter, 3(35): 49–56.

13. Reich K, et al. (2005). Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet, 366(9494): 1367–1374.

14. Krueger GG, et al. (2005). Patient-reported outcomes of psoriasis improvement with etanercept therapy: Results of a randomized phase III trial. British Journal of Dermatology, 153(6): 1192–1199.

15. Aloe (2004). In A DerMarderosian, J Beutler, eds., Review of Natural Products. St. Louis: Wolters Kluwer Health.

Other Works Consulted

• Krueger G, et al. (2000). Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? Journal of the American Academy of Dermatology, 43(2, Part 1): 281–285.

• Krueger G, et al. (2001). The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Archives of Dermatology, 137(3): 280–284.

• Wahl A, et al. (2000). The burden of psoriasis: A study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. Journal of the American Academy of Dermatology, 43(5, Part 1): 803–808.